Cargando…
Modulation of Immunity by Antiangiogenic Molecules in Cancer
In the last decades a new class of therapeutic drugs have been developed that block tumor angiogenesis. These antiangiogenic molecules, which target VEGF or VEGFR, PDGFR, and c-kit, can act not only on endothelial cells but also on immune cells. Some antiangiogenic molecules inhibit the development...
Autores principales: | Terme, Magali, Colussi, Orianne, Marcheteau, Elie, Tanchot, Corinne, Tartour, Eric, Taieb, Julien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540780/ https://www.ncbi.nlm.nih.gov/pubmed/23320019 http://dx.doi.org/10.1155/2012/492920 |
Ejemplares similares
-
Control of the Immune Response by Pro-Angiogenic Factors
por: Voron, Thibault, et al.
Publicado: (2014) -
Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
por: Mougel, Alice, et al.
Publicado: (2019) -
VEGF-A modulates expression of inhibitory checkpoints on CD8(+) T cells in tumors
por: Voron, Thibault, et al.
Publicado: (2015) -
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
por: Terme, Magali, et al.
Publicado: (2013) -
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
por: Pere, Helene, et al.
Publicado: (2012)